We use cookies to ensure that we give you the best website experience. By continuing to use this site, you are agreeing to our use of cookies.


The information on this site is intended to be useful and informative for stakeholders in Kyowa Kirin International. Please note that Kyowa Kirin International cannot guarantee the information is accurate and it shall not be liable for any losses or damage that anyone may suffer as a result of relying on this information. The information may be changed by Kyowa Kirin International at any time.

We make no warranties representations or give any undertakings either express or implied about any of the content of this website (including, without limitation, the timeliness and currency of the website.). You expressly agree that the use of this website and information obtained or downloaded from or through this website is at your sole discretion and risk.


Modern Slavery Act Transparency Statement

Kyowa Kirin is committed to ensuring that there is no modern slavery or human trafficking in our supply chains or in any part of our business. We are committed to acting ethically and with integrity in all of our business relationships and to implementing and enforcing effective systems and controls to ensure slavery and human trafficking is not taking place in any of our supply chains. We have a zero tolerance to slavery and human trafficking.

This statement is made by Kyowa Kirin International plc (“KKI”) and its subsidiaries which include:

  • Strakan International SA
  • Kyowa Kirin Services Limited
  • Kyowa Kirin Sàrl
  • Kyowa Kirin Holdings B.V.
  • Kyowa Kirin, Inc.
  • Kyowa Kirin Limited
  • Kyowa Kirin Pharmaceutical Development Limited
  • Kyowa Kirin Ireland Limited
  • Kyowa Kirin Pharma s.r.o
  • Kyowa Kirin Pharma FZ-LLC
  • Kyowa Kirin Canada, Inc.
  • Kyowa Kirin GmbH
  • Kyowa Kirin AB
  • Kyowa Kirin Pharma B.V.
  • Kyowa Kirin S.r.l.
  • Kyowa Kirin Holdings B.V., French PE]
  • Kyowa Kirin Pharma SAS
  • Kyowa Kirin Farmacéutica, S.L.U.
  • Kyowa Kirin Austria GmbH
  • Kyowa Kirin Farmacêutica, Unipessoal Lda.
  • Archimedes Pharma Limited
  • Archimedes Pharma UK Ltd

pursuant to Section 54(1) of the Modern Slavery Act 2015 (the “Act”) and covers the financial year ending 31 December 2018. KKI is a wholly owned subsidiary of Kyowa Kirin Co., Ltd. a company incorporated in Japan and listed on the Tokyo Stock Exchange.

The Kyowa Kirin Group is an R&D based pharmaceutical company with special strengths in biotechnology. The KHK Group strives to contribute to the health and well-being of people around the world, by creating new value through the pursuit of advances in life sciences and technologies.

KKI has its head office in the UK and trading companies across Europe and the USA marketing and distributing our pharmaceutical products.


Our Supply Chains

KKI outsources its manufacturing and packaging requirements to third parties, including the supply of active pharmaceutical ingredients.

In December 2015 we began undertaking a supply chain surveillance exercise in order to ensure that our third party suppliers do not engage in any activities or behaviour in contravention of the Act. We will continue to monitor our supply chain partners to ensure compliance with the Act.

In addition we are taking steps to review and amend our contractual relationships with our suppliers to obtain written, binding statements to this effect. This process is ongoing and will form part of our regular business review meetings with our suppliers.

This Modern Slavery Act Transparency Statement was approved by the Board of Directors of Kyowa Kirin International plc on 25 January 2019.

Thomas Stratford
Chief Executive Officer